{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ATC&page=3", "query": { "intervention": "ATC", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 89, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ATC&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ATC&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T23:50:16.390Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00251628", "title": "Home Care Management of Pediatric Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Tonsillectomy" ], "interventions": [ { "name": "Standard Care", "type": "OTHER" }, { "name": "ATC Dosing", "type": "OTHER" }, { "name": "Structured Pain Management Program", "type": "OTHER" }, { "name": "As needed dosing", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "15 Years", "sex": "ALL", "summary": "6 Years to 15 Years" }, "enrollment_count": 211, "start_date": "2000-06", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2012-06-08", "last_synced_at": "2026-11-14T23:50:16.390Z", "location_count": 1, "location_summary": "Madera, California", "locations": [ { "city": "Madera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00251628" }, { "nct_id": "NCT04913285", "title": "A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Non-small Cell Lung Cancer", "Melanoma" ], "interventions": [ { "name": "KIN-2787", "type": "DRUG" }, { "name": "KIN-2787 and binimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pierre Fabre Medicament", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2021-08-04", "completion_date": "2029-03-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-11-14T23:50:16.390Z", "location_count": 15, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04913285" }, { "nct_id": "NCT04768296", "title": "Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small-cell Lung Cancer" ], "interventions": [ { "name": "Berzosertib", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2021-03-29", "completion_date": "2023-07-21", "has_results": true, "last_update_posted_date": "2024-09-26", "last_synced_at": "2026-11-14T23:50:16.390Z", "location_count": 12, "location_summary": "Santa Rosa, California • Topeka, Kansas • Bethesda, Maryland + 8 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Topeka", "state": "Kansas" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04768296" }, { "nct_id": "NCT04589845", "title": "Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" }, { "name": "Inavolisib", "type": "DRUG" }, { "name": "Belvarafenib", "type": "DRUG" }, { "name": "Pralsetinib", "type": "DRUG" }, { "name": "Divarasib", "type": "DRUG" }, { "name": "Camonsertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 920, "start_date": "2021-01-18", "completion_date": "2032-09-25", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-11-14T23:50:16.390Z", "location_count": 32, "location_summary": "Goodyear, Arizona • Los Angeles, California • Newport Beach, California + 25 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04589845" }, { "nct_id": "NCT00003782", "title": "Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 5351, "start_date": "1999-03", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2024-03-21", "last_synced_at": "2026-11-14T23:50:16.390Z", "location_count": 146, "location_summary": "Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 123 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003782" }, { "nct_id": "NCT03563053", "title": "Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ataxia Telangiectasia", "Genetic Syndrome" ], "interventions": [ { "name": "EryDex System", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Quince Therapeutics S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 104, "start_date": "2018-06-12", "completion_date": "2022-09-02", "has_results": true, "last_update_posted_date": "2024-10-08", "last_synced_at": "2026-11-14T23:50:16.390Z", "location_count": 4, "location_summary": "Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563053" }, { "nct_id": "NCT00972075", "title": "Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-24 Hour Sleep-Wake Disorder", "Blindness" ], "interventions": [ { "name": "melatonin (Circadin)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neurim Pharmaceuticals Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "20 Years to 80 Years" }, "enrollment_count": 13, "start_date": "2006-02", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2009-09-09", "last_synced_at": "2026-11-14T23:50:16.390Z", "location_count": 2, "location_summary": "Atlanta, Georgia • New York, New York", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00972075" }, { "nct_id": "NCT05110313", "title": "Effects of Tildrakizumab on Epigenetic Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis", "Aging", "Epigenetic Disorder", "Inflammation; Skin" ], "interventions": [ { "name": "TILDRAKIZUMAB", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Carlos Wambier", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "ALL", "summary": "35 Years and older" }, "enrollment_count": 30, "start_date": "2022-04-08", "completion_date": "2024-05-27", "has_results": false, "last_update_posted_date": "2024-07-18", "last_synced_at": "2026-11-14T23:50:16.390Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT05110313" }, { "nct_id": "NCT02244463", "title": "A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anaplastic Thyroid Cancer", "Thyroid Cancer", "Differentiated Thyroid Cancer" ], "interventions": [ { "name": "MLN0128", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2015-07", "completion_date": "2022-04-28", "has_results": true, "last_update_posted_date": "2024-01-12", "last_synced_at": "2026-11-14T23:50:16.390Z", "location_count": 3, "location_summary": "Newport Beach, California • Boston, Massachusetts • Ann Arbor, Michigan", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02244463" }, { "nct_id": "NCT01942850", "title": "International Ataxia Rating Scale in Younger Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ataxia Telangiectasia" ], "interventions": [], "intervention_types": [], "sponsor": "Quince Therapeutics S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Years to 18 Years" }, "enrollment_count": 63, "start_date": "2013-08", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-12-31", "last_synced_at": "2026-11-14T23:50:16.390Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01942850" } ] }